Trends and Present Treatment Patterns of Early Breast Cancer in Southwest China

被引:9
作者
Hu, Qiancheng [1 ,2 ,3 ]
Luo, Ting [1 ,2 ,3 ]
He, Ping [1 ,2 ,3 ]
Zhong, Xiaorong [1 ,2 ,3 ]
Tian, Tinglun [1 ,2 ,3 ]
Lv, Qing [4 ]
Yan, Xi [1 ,2 ,3 ]
Zheng, Hong [1 ,2 ,3 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Head & Neck & Mammary Oncol, Chengdu 610041, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Med Oncol, Ctr Canc, Chengdu 610041, Peoples R China
[3] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Lab Mol Diag Canc, Chengdu 610041, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Thyroid & Breast Surg, Chengdu 610041, Peoples R China
关键词
Early breast cancer; Southwest China; Trends; Present treatment; INTERNATIONAL EXPERT CONSENSUS; PRIMARY THERAPY; POSTMENOPAUSAL WOMEN; ADJUVANT TREATMENT; RANDOMIZED-TRIAL; FOLLOW-UP; HIGHLIGHTS; TAMOXIFEN; SUBTYPES; ESTROGEN;
D O I
10.1007/s12253-014-9829-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To analyze the changing patterns of treatment and to explore the current treatment approaches for breast cancer in Southwest China, we conducted a population-based retrospective cohort study of early breast cancer cases. The data of patients who registered in the information management system for breast cancer in Huaxi Hospital, Sichuan University from 1989 to 2012 were extracted. Nearly all patients underwent surgery, among whom radical mastectomy was the predominant option. Chemotherapy (88.7 %) was the most predominant adjuvant therapy approach. The percentage of patients receiving radiation therapy displayed fluctuant increase, which was 37.1 % in 2001 and reached up to 67.6 % in 2011. Besides, the endocrinetherapy became more and more popular in the hormone-receptor positive patients and the percentage of endocrinetherapy was increased from 54.1 at 2001 to 85.6 % at 2011. However, more than 10 % of hormone-receptor positive patients still did not receive endocrinetherapy annually. The hormone-receptor positive patients who received endocrinetherapy had better 5-year disease free survival (DFS) and overall survival (OS) compared to those without endocrinetherapy (5-y DFS: 88.4 % vs. 75.1 %, P < 0.001; 5-y OS: 95.7 % vs. 88.4 %, P < 0.001). N stage appeared to have greater impact on the 5-year DFS and OS than molecular subtyping. The treatment for breast cancer in China has been significantly improved but more attentions should be paid to radiotherapy and endocrine therapy. In addition, the value of N stage in the prognosis of breast cancer should not be ignored when the molecular typing draws more and more attentions.
引用
收藏
页码:367 / 378
页数:12
相关论文
共 44 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]   Early discontinuation of tamoxifen - A lesson for oncologists [J].
Barron, Thomas I. ;
Connolly, Roisin M. ;
Bennett, Kathleen ;
Feely, John ;
Kennedy, M. John .
CANCER, 2007, 109 (05) :832-839
[3]   Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].
Bauer, Katrina R. ;
Brown, Monica ;
Cress, Rosemary D. ;
Parise, Carol A. ;
Caggiano, Vincent .
CANCER, 2007, 109 (09) :1721-1728
[4]  
Baum M, 2002, LANCET, V359, P2131
[5]   Effect of screening and adjuvant therapy on mortality from breast cancer [J].
Berry, DA ;
Cronin, KA ;
Plevritis, SK ;
Fryback, DG ;
Clarke, L ;
Zelen, M ;
Mandelblatt, JS ;
Yakovlev, AY ;
Habbema, JDF ;
Feuer, EJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (17) :1784-1792
[6]   Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J].
Carey, Lisa A. ;
Perou, Charles M. ;
Livasy, Chad A. ;
Dressler, Lynn G. ;
Cowan, David ;
Conway, Kathleen ;
Karaca, Gamze ;
Troester, Melissa A. ;
Tse, Chiu Kit ;
Edmiston, Sharon ;
Deming, Sandra L. ;
Geradts, Joseph ;
Cheang, Maggie C. U. ;
Nielsen, Torsten O. ;
Moorman, Patricia G. ;
Earp, H. Shelton ;
Millikan, Robert C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2492-2502
[7]   A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [J].
Coombes, RC ;
Hall, E ;
Gibson, LJ ;
Paridaens, R ;
Jassem, J ;
Delozier, T ;
Jones, SE ;
Alvarez, I ;
Bertelli, G ;
Ortmann, O ;
Coates, AS ;
Bajetta, E ;
Dodwell, D ;
Coleman, RE ;
Fallowfield, LJ ;
Mickiewicz, E ;
Andersen, J ;
Lonning, PE ;
Cocconi, G ;
Stewart, A ;
Stuart, N ;
Snowdon, CF ;
Carpentieri, M ;
Massimini, G ;
Bliss, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) :1081-1092
[8]   Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status [J].
Dixon, JM ;
Jackson, J ;
Hills, M ;
Renshaw, L ;
Cameron, DA ;
Anderson, TJ ;
Miller, WR ;
Dowsett, M .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (18) :2742-2747
[9]   Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients [J].
Eggemann, Holm ;
Ignatov, Atanas ;
Smith, Bobbie J. ;
Altmann, Udo ;
von Minckwitz, Gunter ;
Roehl, Freidrich W. ;
Jahn, Mark ;
Costa, Serban-Dan .
BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (02) :465-470
[10]   Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial [J].
Ellis, MJ ;
Coop, A ;
Singh, B ;
Mauriac, L ;
Llombert-Cussac, A ;
Jänicke, F ;
Miller, WR ;
Evans, DB ;
Dugan, M ;
Brady, C ;
Quebe-Fehling, E ;
Borgs, M .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) :3808-3816